These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 2540054

  • 1. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial.
    Baba T, Murabayashi S, Takebe K.
    Diabetologia; 1989 Jan; 32(1):40-4. PubMed ID: 2540054
    [Abstract] [Full Text] [Related]

  • 2. Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non-insulin-dependent) diabetic patients with and without nephropathy.
    Baba T, Tomiyama T, Murabayashi S, Takebe K.
    Eur J Clin Pharmacol; 1990 Jan; 38(5):425-9. PubMed ID: 2379527
    [Abstract] [Full Text] [Related]

  • 3. Effect of nicardipine versus enalapril on plasma endothelin-1 in hypertensive patients with type 2 diabetes mellitus.
    Iwase M, Doi Y, Goto D, Ichikawa K, Iino K, Yoshinari M, Fujishima M.
    Clin Exp Hypertens; 2000 Jan; 22(7-8):695-703. PubMed ID: 11131046
    [Abstract] [Full Text] [Related]

  • 4. Beneficial effects of angiotensin-converting enzyme inhibitor on renal function and glucose homeostasis in diabetics with hypertension.
    Ueda Y, Aoi W, Yamachika S, Shikaya T.
    Nephron; 1990 Jan; 55 Suppl 1():85-9. PubMed ID: 2189076
    [Abstract] [Full Text] [Related]

  • 5. Effects of enalapril and nitrendipine on the excretion of epidermal growth factor and albumin in hypertensive NIDDM patients.
    Josefsberg Z, Ross SA, Lev-Ran A, Hwang DL.
    Diabetes Care; 1995 May; 18(5):690-3. PubMed ID: 8586009
    [Abstract] [Full Text] [Related]

  • 6. Effects of angiotensin-converting enzyme inhibitor (alacepril) and calcium antagonist (nicardipine) in hypertensive non-insulin-dependent diabetic patients with microalbuminuria.
    Haisa S, Norii T, Takatori E, Goto A, Morioka S, Uchida K, Himei H.
    J Diabet Complications; 1991 May; 5(2-3):162-4. PubMed ID: 1770031
    [Abstract] [Full Text] [Related]

  • 7. Renal effects of nicardipine, a calcium entry blocker, in hypertensive type II diabetic patients with nephropathy.
    Baba T, Ishizaki T, Ido Y, Aoyagi K, Murabayashi S, Takebe K.
    Diabetes; 1986 Nov; 35(11):1206-14. PubMed ID: 3530849
    [Abstract] [Full Text] [Related]

  • 8. Low-dose angiotensin converting enzyme inhibitors: effect on renal function in normo- and hypertensive type 1 diabetic patients.
    Ciavarella A, Mustacchio A, Silletti A, Franchi R, Levorato M, Campieri C, Borgnino LC, Capozzi G, Morotti L, Vannini P.
    Eur J Med; 1992 Sep; 1(5):268-72. PubMed ID: 1341608
    [Abstract] [Full Text] [Related]

  • 9. Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM.
    Chan JC, Nicholls MG, Cheung CK, Law LK, Swaminathan R, Cockram CS.
    Diabetes Care; 1995 Jul; 18(7):1001-6. PubMed ID: 7555530
    [Abstract] [Full Text] [Related]

  • 10. Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension.
    Sánchez RA, Marcó E, Gilbert HB, Raffaele P, Brito M, Giménez M, Moledo LI.
    Drugs; 1985 Jul; 30 Suppl 1():49-58. PubMed ID: 2994987
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria.
    Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA.
    Kidney Int Suppl; 1994 Feb; 45():S150-5. PubMed ID: 8158885
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mechanisms of renal hemodynamic impairment during infrarenal aortic cross-clamping.
    Colson P, Ribstein J, Séguin JR, Marty-Ane C, Roquefeuil B.
    Anesth Analg; 1992 Jul; 75(1):18-23. PubMed ID: 1616156
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Norepinephrine-induced blood pressure rise and renal vasoconstriction are not attenuated by enalapril treatment in microalbuminuric IDDM.
    Hoogenberg K, Navis G, Dullaart RP.
    Nephrol Dial Transplant; 1998 Mar; 13(3):640-5. PubMed ID: 9550640
    [Abstract] [Full Text] [Related]

  • 17. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria.
    Ahmad J, Siddiqui MA, Ahmad H.
    Diabetes Care; 1997 Oct; 20(10):1576-81. PubMed ID: 9314638
    [Abstract] [Full Text] [Related]

  • 18. Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
    Fabris B, Candido R, Armini L, Fischetti F, Calci M, Bardelli M, Fazio M, Campanacci L, Carretta R.
    J Hypertens; 1999 Dec; 17(12 Pt 2):1925-31. PubMed ID: 10703891
    [Abstract] [Full Text] [Related]

  • 19. Contrasting effects of angiotensin converting inhibitor and alpha-1-antagonist on albuminuria in insulin-dependent diabetes mellitus patients with nephropathy.
    Holdaas H, Hartmann A, Berg KJ, Langberg H, Blystad L, Fauchald P.
    J Intern Med; 1995 Jan; 237(1):63-71. PubMed ID: 7830033
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.